Alcohol-Associated Liver Disease: Comprehensive Lecture Summary
By Dr. Ashwani K. Singal, MD
1. Main Clinical Topics Discussed
- Epidemiology and healthcare burden of alcohol-associated liver disease (ALD)
- Spectrum of ALD: from steatosis to cirrhosis and hepatocellular carcinoma
- Risk factors, protective factors, and genetic contributors
- Screening tools for alcohol use disorder (AUD) and liver disease
- Diagnostic approach including non-invasive fibrosis assessment
- Recognition and management of alcoholic hepatitis (AH)
- Integration of addiction medicine with hepatology care
2. Key Learning Points, Guidelines, and Recommendations
Screening for Alcohol Use Disorder
- AUDIT-C (first 3 questions of the full AUDIT tool) is recommended for routine clinical screening:
- Frequency of drinking
- Number of drinks on a typical day
- Frequency of consuming ≥5 drinks on one occasion
- Scoring thresholds: Score >4 in females, >5 in males indicates high likelihood of AUD
- DSM-5 criteria: ≥4 of 11 criteria (covering consumption patterns, tolerance, withdrawal, and social/physical impact) indicates AUD
- All clinicians — not only hepatologists, but also internists, family medicine physicians, ED physicians, residents, and students — should routinely screen for AUD, analogous to smoking screening
Liver Disease Screening in At-Risk Individuals
- Recommended by both EASL and AASLD: screen at-risk individuals with basic metabolic panel, CBC, and abdominal ultrasound
- Primary goal: determine presence or absence of cirrhosis
- If cirrhosis is absent, assess risk for advanced fibrosis using non-invasive markers:
- FIB-4: preferred due to accessibility; no additional lab tests required
- ELF score / FibroTest: more accurate but proprietary and not widely available
- FibroScan (transient elastography): cutoff of ≥15 kPa suggests advanced fibrosis; treat as cirrhosis
- MRE or liver biopsy reserved for selected cases
Risk Stratification and Referral
- High-risk fibrosis / cirrhosis: Refer to hepatology; initiate:
- Hepatocellular carcinoma (HCC) surveillance
- Endoscopic variceal screening
- Hepatitis A and B vaccination
- Liver transplant evaluation as appropriate
- Low-to-intermediate fibrosis risk: Return to community care; follow-up every 3–5 years
- AUD severity-based referral:
- AUDIT score <8: No AUD
- AUDIT 8–20: Mild AUD — brief intervention by hepatologist
- AUDIT >20: Moderate-to-severe AUD — refer to integrated addiction medicine
3. Specific Clinical Data, Statistics, and Study Results Cited
- Global prevalence of AUD: ~2% worldwide; ~4% in Europe
- Cirrhosis mortality attributable to alcohol:
- ~27% worldwide
- ~40% in Europe
- 30–40% in South America
- Liver transplantation: ALD is the leading indication for liver transplantation in the U.S.; accounted for 40–45% of transplants in 2018
- Hospitalization trends (National Inpatient Sample, 2006–2016): Rising admissions for both alcohol-associated cirrhosis and alcoholic hepatitis, disproportionately affecting:
- Patients <35 years of age
- Females and Hispanics, who present with more severe disease (alcohol-associated ACLF)
- Alcohol dose-response for cirrhosis risk:
- Risk begins to rise at ~50 g/day
- Modest increase up to 100 g/day
- Exponential increase beyond 100 g/day
- Only 10–20% of heavy drinkers develop cirrhosis, indicating the importance of modifying risk factors
- Gender-specific cirrhosis risk (15-year study, >